Cancer Treatment Reviews
Volume 29, Supplement 1 , Pages 21-31, May 2003

Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib

  • James C. Cusack

      Affiliations

    • Corresponding Author InformationCorrespondence to: James C. Cusack, Jr, MD, Harvard Medical School, Massachusetts General Hospital Boston, MA 02114, USA. Tel.: +1-617-724-4093; fax: +1-617-724-3895

Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0305-7372(03)00079-3

doi:10.1016/S0305-7372(03)00079-3

Cancer Treatment Reviews
Volume 29, Supplement 1 , Pages 21-31, May 2003

Article Tools

* Image Usage & Resolution